Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05477576 · ClinicalTrials.gov registry record · Phase 3
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
A Phase 3 study of Neuroendocrine Tumors and Carcinoid Tumor, sponsored by RayzeBio.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 288
- Enrollment target
- 20
- Study locations
NCT05477576 is a Phase 3 study of Neuroendocrine Tumors and Carcinoid Tumor that is actively recruiting participants, run by RayzeBio. The registered enrollment target is 288 participants, above the 174-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (66% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT05477576, a Phase 3 study of Neuroendocrine Tumors and Carcinoid Tumor, is actively recruiting participants, sponsored by RayzeBio.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 288 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment with Lutetium 177-labelled somatostatin analogue (177Lu-SSA) therapy, such as 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC), or 177Lu-high affinity \[HA\]-DOTATATE.
Conditions Studied
Interventions
- DRUG Everolimus
- DRUG Sunitinib
- DRUG Lanreotide
- DRUG RYZ101
- DRUG Octreotide
Study Locations (20)
California
- Research Facility - Duarte
- Research Facility - Irvine
- Research Facility - Los Angeles
- Research Facility - Palo Alto
- Research Facility - San Francisco
Florida
- Research Facility - Jacksonville
- Research Facility - Miami
- Research Facility - Tampa
Massachusetts
- Research Facility - Boston
- Research Facility - Boston
Arizona
- Research Facility - Phoenix
Connecticut
- Research Facility - New Haven
District of Columbia
- Research Facility - Washington D.C.
Georgia
- Research Facility - Atlanta
Iowa
- Research Facility - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2022-03-24 |
| Est. Completion | 2028-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05477576
The ClinicalTrials.gov registry entry for NCT05477576 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 288 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 174-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (66% higher). The listed sponsor is RayzeBio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 5 interventions - of which Everolimus is the first listed.
NCT05477576 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05477576 about?
NCT05477576 is a clinical study titled "Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy". This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, ...
What is the current status of trial NCT05477576?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 288 participants. The study started on 2022-03-24. Estimated completion is 2028-07.
What conditions does trial NCT05477576 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Carcinoid Tumor, Gastroenteropancreatic Neuroendocrine Tumor, Carcinoid, GEP-NET.
What interventions are being tested in trial NCT05477576?
The interventions under investigation include: Everolimus (DRUG), Sunitinib (DRUG), Lanreotide (DRUG), RYZ101 (DRUG), Octreotide (DRUG).
Who is sponsoring clinical trial NCT05477576?
This trial is sponsored by RayzeBio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05477576 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
ACTIVE NOT RECRUITING · Phase 3
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.